6CM
ESPR icon

683 Capital Management’s Esperion Therapeutics ESPR Stock Holding History

683 Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-134,689
Closed -$403K – 169
2023
Q4 		$403K Buy
+134,689
New +$175K 0.03% 98

Other funds holding ESPR

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

683 Capital Management's ESPR Position: Q1 2024 in Review

683 Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 134,689 shares — an estimated $403K sold.

683 Capital Management first reported a position in ESPR in Q4 2023 and held it in 1 quarter. The position peaked at $403K in Q4 2023. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

  • 683 Capital Management reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 134,689 Esperion Therapeutics shares in Q1 2024, an estimated $403K.
  • 683 Capital Management first reported a position in Esperion Therapeutics in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Esperion Therapeutics position peaked at $403K in Q4 2023.
  • 153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.